Technology licensing gives a company the legal right to use someone else's intellectual property. Technology transfer gives it the practical ability to do the work: the documentation, materials, training and process knowledge needed to reproduce a product consistently. In biotechnology the two are often negotiated together, but they are different things. A deal that covers only licensing can leave a buyer holding rights it cannot use. A deal that covers only know-how can leave it using knowledge it has no right to exploit. For cell therapy, gene therapy, biologics and molecular diagnostics, where manufacturing knowledge often matters as much as the patent, the distinction decides whether a project ends in a product or only in a contract.
Key takeaways
- Licensing is about rights. Transfer is about capability.
- Most complex biotech deals need both, plus training and technical support.
- Neither one moves ownership. That requires a separate assignment.
- A patent describes an invention. It rarely contains everything needed to manufacture a living-cell product reliably.
- Define deliverables, acceptance criteria and ownership of improvements in writing before work begins.
What is technology licensing?
A licence is permission. The owner of the intellectual property (the licensor) allows another party (the licensee) to use defined rights under agreed conditions, usually for a fee. WIPO's licensing manual notes that licensing involves exchanging intellectual property for money or something else of value, and that intellectual property here is a broad idea covering patents, copyright in technical documents, know-how and trade secrets.
The licensor normally keeps ownership. What the licensee gets is a defined bundle of permissions. These may include the right to make, use, sell, import or sublicense, and they are limited by territory, field and time.
In biotech, licensed assets include a CAR construct, a viral-vector platform, an antibody, a cell-culture method, a diagnostic biomarker, or a proprietary manufacturing process.
What is technology transfer?
Technology transfer is the movement of the ability to make something work. In pharmaceutical manufacturing, WHO's guidance frames it as a controlled process in which a sending unit passes a process, with its documentation and expertise, to a receiving unit. The 2011 edition stresses that a transfer involves both documentation and the receiving unit's demonstrated ability to carry out the critical elements of the transferred technology. The current edition is WHO Technical Report Series No. 1044, Annex 4 (2022), which replaced the 2011 text.
The idea of demonstrated ability matters. A transfer is not complete when the documents are handed over. It is complete when the receiving team can perform the process and meet the agreed specifications.
A biotech transfer package commonly includes:
- Standard operating procedures, master batch records and process parameters
- Raw-material, equipment and facility requirements
- Analytical and release-testing methods
- Biological materials such as cell banks, plasmids or vectors, under a material transfer agreement
- Training, on-site support and troubleshooting
- Supporting data for regulatory submissions, where legally permitted and contractually agreed
Licensing vs technology transfer at a glance
Area | Technology licensing | Technology transfer |
|---|---|---|
Core purpose | Grant legal rights | Enable practical implementation |
What changes hands | Permission to use IP | Know-how, documents, materials, training |
Ownership | Stays with licensor | Stays with provider unless IP is separately assigned |
Patents | Usually central | One component among several |
Training and support | Optional | Often essential |
Success measure | Rights granted and terms met | Receiving site reproduces the process to specification |
Typical payments | Upfront fee, milestones, royalties | Transfer fee, training and support fees, often alongside licence economics |
Main risk | Rights without capability | Capability without clear rights |
Why the two usually travel together
Take a hypothetical example. A developer holds a proprietary CAR-T therapy and wants a partner in another country.
A licence alone might give the partner the right to manufacture and commercialise in a defined territory. The partner must still work out how to make the product. For a living-cell therapy, that can take years.
A licence plus transfer adds the vector process, cell isolation, activation, transduction and expansion methods, cryopreservation, quality-control and potency assays, batch records, staff training and supervised engineering batches.
The second arrangement costs more and takes more coordination. It is also the one that produces a working local capability. This example is illustrative and does not describe any specific transaction. For the full sequence in a cell therapy, see how to transfer CAR-T cell therapy technology.
Why biotech makes transfer harder
Manufacturing a mechanical part from drawings is largely a matter of following dimensions. Manufacturing a cell therapy depends on starting-material quality, media and reagent lots, timing between steps, operator technique, environmental controls and equipment. Small differences can change the product.
Much of this knowledge is tacit. Experienced scientists know what a healthy culture looks like, when a step is starting to drift, and which parameters are sensitive. A manual rarely captures this fully. Successful transfers therefore include person-to-person training and supervised runs, not just documents.
Common licence structures
Structure | What it means |
|---|---|
Exclusive | One licensee holds the rights within the agreed scope. NIH describes this as limiting use of the invention to a single entity in a particular field of use. |
Non-exclusive | Multiple entities may use the invention within the same field. Common for research tools and platform technologies. |
Sole | Typically one licensee plus the licensor's own retained rights. Definitions vary between contracts, so state the meaning explicitly. |
Territorial | Rights limited to a country or region, which lets an owner use different partners in different markets. |
Field-of-use | Rights limited to an application, such as oncology only. |
NIH also licenses unpatented biological materials, which shows that valuable biotech assets do not always depend on a patent. Its licence families include patent licences, biological materials licences and evaluation licences.
How the money usually works
Licence economics commonly combine an upfront payment, development and regulatory milestones, commercial milestones and royalties, plus a share of sublicensing income where applicable.
Transfer economics add charges for the transfer package itself, training, supervised engineering batches, facility-setup advice and validation or analytical support.
Actual figures depend on technology maturity, patent position, exclusivity, territory and competition. This article does not quote benchmark numbers, because published figures vary widely and should be sourced for each deal.
What a transfer agreement should pin down
- Technology definition: patents, applications, know-how, data, materials, SOPs and software, listed specifically.
- Territory, field and exclusivity.
- A deliverables schedule: itemised documents, methods and materials, not a promise of "all necessary know-how".
- A staged timeline: documentation, training, facility readiness, engineering batches, method qualification, process validation.
- Training scope: number of trainees, duration, location, language and travel costs.
- Acceptance criteria: objective tests for when the transfer counts as complete, such as reproducible batches meeting specification.
- Background IP, foreground IP and improvements: who owns what, and who may use it. This is among the most negotiated clauses.
- Confidentiality and trade-secret protection for unpatented know-how.
- Regulatory and quality responsibilities, usually backed by a separate quality agreement covering deviations, change control, batch release and audits.
- Supply: interim supply of vectors, plasmids or critical reagents.
- Change control for the process, and what happens on termination.
Documentation
Training
Facility readiness
Engineering batches
Method qualification
Process validation
WIPO's licensing materials flag the same core issues: exclusivity, sublicensing, territory, duration, financial terms, improvements, warranties and dispute settlement.
Cross-border considerations
Moving technology between countries adds layers that a domestic deal does not have:
- IP coverage: patents are national or regional, so check where protection exists before sharing sensitive know-how.
- Regulation: the receiving country sets its own rules on clinical development, GMP, cell processing and genetic modification.
- Trade controls and material import: some equipment and biological materials need permits.
- Tax and payments: royalties and service fees can attract withholding tax. Seek local tax advice.
- Disputes: specify governing law, forum and arbitration seat.
India is a useful illustration. India's New Drugs and Clinical Trials Rules, 2019 define "new drug" to include cell, stem-cell and gene-therapy products, so these products enter the formal approval framework. The bodies typically involved include CDSCO, RCGM and GTAEC, with roles that depend on the product and stage. Confirm the current pathway with qualified Indian regulatory counsel before committing capital.
India has also approved a domestically developed CAR-T product: CDSCO authorised ImmunoACT's NexCAR19, a CD19-targeted therapy, on 13 October 2023. That makes local manufacturing capability a live, benchmarkable reference when partners assess what a transfer must achieve.
Technical feasibility and regulatory permission are separate questions. A process that works in the sending country still needs local regulatory acceptance.
Common mistakes
Mistake | Fix |
|---|---|
Negotiating only the patent licence and assuming manufacturing follows. | Scope the whole transfer package. |
Missing critical materials, such as a proprietary reagent that cannot be sourced locally. | Run a materials and supplier assessment early. |
Underestimating the receiving facility. | Do a gap analysis against the process before signing. WHO's guidance highlights a technical gap analysis and due diligence covering technical and regulatory aspects. |
Leaving improvements unaddressed. | Agree ownership and licence-back terms upfront. |
No acceptance criteria. | Define measurable success before work starts. |
Skipping regulatory feasibility. | Assess local requirements before major capital commitments. |
Which structure fits?
Situation | Typical structure |
|---|---|
Buyer already has manufacturing capability and needs commercial rights | Licence, limited transfer |
Provider keeps manufacturing and the partner only markets | Licence plus supply agreement |
Manufacturing is outsourced to a CDMO | Licence, with a transfer to the CDMO |
Buyer needs local manufacturing for a complex process | Licence plus full technology transfer and training |
Buyer wants permanent, unrestricted control | Acquisition or IP assignment |
Due-diligence checklist
Area | What to check |
|---|---|
IP | Owners, jurisdictions, expiry dates, third-party dependencies, freedom to operate |
Science and clinical | Reproducibility, independent validation, trial data, development still required |
Manufacturing and quality | Scalability, critical materials, documented specifications, transferable assays |
Regulatory | Existing approvals, local requirements, who files what |
Commercial and financial | Market size, competitors, pricing, capital and operating costs, payment terms |
Partner capability | The provider's ability to support the transfer and the recipient's ability to absorb it |
Frequently asked questions
Is technology licensing the same as technology transfer?
No. Licensing grants rights to use intellectual property. Technology transfer moves the know-how, materials and training needed to implement the technology. Many deals include both.
Can technology be transferred without a patent licence?
Yes, where the value lies in unpatented know-how or materials. Such arrangements still need a contract covering permitted use, confidentiality and ownership.
Does the recipient own the technology after transfer?
Not unless the IP is formally assigned. Usually the provider keeps ownership and the recipient operates under defined rights.
What is the difference between exclusive and non-exclusive licensing?
Exclusive licensing gives one licensee the rights within an agreed scope. Non-exclusive licensing allows several licensees to use the same technology. Scope can be set by territory, product or field.
What is the biggest risk in biotech technology transfer?
Assuming documents are enough. Biological processes depend on practical experience, so training, supervised runs and technical support are central.
How long does a transfer take?
There is no universal timeline. It depends on process complexity, facility readiness, training needs and regulatory steps. A gap assessment for the specific technology gives a realistic estimate.
Conclusion
The useful question is not "can we license this technology?" It is "can we reproduce, regulate, manufacture and commercialise it in our market?" A licence answers the first part. A well-structured transfer answers the rest. For complex platforms such as CAR-T, gene therapy and advanced biologics, the strongest deals pair clear IP rights with a defined, measurable transfer of capability.
Exploring Biotechnology Technology Transfer in India or Asia?
VectorGene Biotech Limited supports hospitals, pharmaceutical manufacturers, biotechnology companies and research institutions in evaluating technology transfer, licensing and localisation opportunities across advanced biomedical platforms. Technology availability and licensing rights are partner-specific and subject to confirmation for each project.
Contact: partnerships@vectorgene.hk | Technology Transfer at VectorGene
Disclaimer: This article is for general information and is not legal, regulatory, tax, financial or investment advice. Licensing, intellectual-property and manufacturing requirements vary by technology and jurisdiction. Engage qualified professionals before entering a transaction.
References
- WIPO, Successful Technology Licensing (Publication 903): https://tind.wipo.int/record/28679/files/wipo_pub_903.pdf
- WIPO, Green Licensing Checklist: https://www3.wipo.int/wipogreen/docs/en/wipogreen_licensingchecklist_061216.pdf
- WHO, Guidelines on technology transfer in pharmaceutical manufacturing, TRS 1044, Annex 4 (2022): https://www.who.int/publications/m/item/trs1044-annex4
- WHO, Guidelines on transfer of technology in pharmaceutical manufacturing, TRS 961, Annex 7 (2011, superseded): https://extranet.who.int/prequal/sites/default/files/document_files/TRS_961_Annex7_2011.pdf
- NIH Office of Technology Transfer, Licensing: https://techtransfer.nih.gov/licensing
- NCI Technology Transfer Center, License Agreements: https://techtransfer.cancer.gov/partnering-with-nih/licensingagreements
- India, New Drugs and Clinical Trials Rules, 2019 (CDSCO)
- BioSpectrum India, ImmunoACT announces CDSCO approval of NexCAR19, 16 October 2023: https://www.biospectrumindia.com/news/20/23709/immunoact-announces-cdsco-approval-of-indias-first-car-t-cell-therapy-nexcar19.html
Sandeep Kumar Wamne
Founder - VectorGene Biotech Limited
